Research programme: CRISPR-based therapeutics - Biogen/Scribe Therapeutics
Latest Information Update: 08 Oct 2020
At a glance
- Originator Scribe Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis
Most Recent Events
- 06 Oct 2020 CRISPR-based therapeutics is available for licensing as of 06 Oct 2020. https://www.scribetx.com/science/
- 06 Oct 2020 Scribe Therapeutics and Biogen agree to co-develop CRISPR-based therapeutics for Amyotrophic lateral sclerosis
- 06 Oct 2020 Early research in Amyotrophic lateral sclerosis in USA (Parenteral)